S10 Ep41: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
In this episode of The Midweek Takeaway, Kevin Hornsby and Charles Archer is joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to discuss positive pre-clinical results from the company’s PTSD programme, SVN-SDN-14. Three high-performing candidates with strong, balanced SERT, DAT, and NET modulation profiles are advancing to in vivo studies — a key step toward developing a new class of medicines aimed at enhancing pro-social behaviour and improving outcomes for people living with PTSD.
Disclaimer & Declaration of Interest
This podcast may contain paid promotions, including…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.